ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 2219 • ACR Convergence 2022

    Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

    Beth Wallace1, Yuqing Gao2, H. Myra Kim3, Punyasha Roul4, Ted Mikuls5, Daniel Clauw6, Bryant England7, Joshua Baker8, Brian Sauer9, Grant Cannon10, Shirley Cohen-Mekelberg1, Wyndy Wiitala2, Jeremy Sussman1, Rodney Hayward1 and Akbar Waljee1, 1University of Michigan Department of Internal Medicine; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, 2Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, 3Center for Statistical Consultation and Research, University of Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare Center, Ann Arbor, MI, 4UNMC, Omaha, NE, 5Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 6University of Michigan Department of Anesthesia, Ann Arbor, MI, 7University of Nebraska Medical Center, Omaha, NE, 8University of Pennsylvania, Philadelphia, PA, 9Salt Lake City VA/University of Utah, Salt Lake City, UT, 10Retired, Salt Lake City, UT

    Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) at some point to manage RA symptoms. Prior work suggests recent GC use is associated with major…
  • Abstract Number: PP19 • ACR Convergence 2022

    Living with Rheumatoid Arthritis in a Rural Farming Community: How I Found a Rheumatologist and Got Targeted Treatment

    Vanessa Kerr, Mexico, MO

    Background/Purpose: I'm Vanessa and I've been married to James, a farmer, for 27 years. We have 5 children and when my fourth was born, I…
  • Abstract Number: 0049 • ACR Convergence 2022

    IL-18 Receptor-α Signaling Pathway Contributes to Autoantibody-induced Arthritis via Neutrophil Recruitment

    Shinjiro Kaieda and Tomoaki Hoshino, Kurume University School of Medicine, Kurume, Japan

    Background/Purpose: We have previously reported that IL-18 levels in the lungs, serum and bronchoalveolar lavage fluid (BALF) were increased in patients with idiopathic pulmonary lung…
  • Abstract Number: 0093 • ACR Convergence 2022

    Comparison of Faculty and Fellow Prescribing Patterns for Rheumatoid Arthritis in an Urban, Academic Hospital

    Ana Valle1, Xianhong Xie2, Don-Andre Jackson3 and Irene Blanco4, 1Montefiore Medical Center, New York, NY, 2Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, 3Griffin Health, Stamford, CT, 4Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Timely initiation of DMARDs in rheumatoid arthritis (RA) is necessary to prevent significant morbidity and mortality. Yet, patients from marginalized groups are less likely…
  • Abstract Number: 0205 • ACR Convergence 2022

    Virtually Training Peer Coaches to Use Motivational Interviewing Skills: Processes from a Rheumatoid Arthritis Intervention Training Program

    Mackenzie Brown1, Yuliana Domínguez Páez2, Assem Jabri3, Geyanne Lui4, Joan Weiner3, Aberdeen Allen5, Tien Sydnor-Campbell6, Shelley fritz3, Megan Creasman7, Shanthini Kasturi8, Monika Safford3 and Iris Navarro-Millan3, 1Weill Cornell Medicine, Brooklyn, NY, 2Weill Cornell Medicine, Bronx, NY, 3Weill Cornell Medicine, New York, NY, 4Albert Einstein College of Medicine, New York, NY, 5Weill Cornell Medicine, Parlin, 6Weill Cornell Medicine, Philedelphia, 7NYP-Weill Cornell, New York, NY, 8Tufts Medical Center, Boston, MA

    Background/Purpose: Peer coaching interventions are effective in helping individuals with chronic conditions understand and manage their disease. Most peer coach training programs occur in person,…
  • Abstract Number: 0253 • ACR Convergence 2022

    Evaluation of Patients with Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic

    Jérôme Avouac1, Anna Molto2, Camelia Frantz3, sarah wanono3, elise descamps4, olivier fogel4, Alice Combier5, lucile poiroux5, Corinne MIceli6 and Yannick Allanore7, 1University of Paris, Paris, France, 2Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France, 3Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 4Hôpital Cochin, AP-HP Centre - Université de Paris Cité, Paris, France, 5Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, 6APHP, Paris, France, 7Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: The sudden emergence of SARS-CoV-2 onto the world stage has accelerated a major change in the management of patients with chronic rheumatic diseases and…
  • Abstract Number: 0269 • ACR Convergence 2022

    Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage

    Marijke van den Dikkenberg1, Martijn Kuijper2, Marc Kok1, Deirisa Lopes Barreto2 and Angelique Weel1, 1Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, 2Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam

    Background/Purpose: In modern Rheumatoid Arthritis (RA) care remote consults (via phone or video call) are increasing. Whereas the Disease Activity Scores (DAS) requires a patient…
  • Abstract Number: 0287 • ACR Convergence 2022

    Association Between Short-Term Response to Upadacitinib Treatment and Long-Term Clinical Outcomes in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Tumor Necrosis Factor Inhibitor Therapy

    Christina Charles-Schoeman1, Roy Fleischmann2, Stephen Hall3, Arthur Kavanaugh4, Andrea Rubbert-Roth5, Ryan DeMasi6, Sara Penn6, Andrew Garrison6, Samuel Anyanwu6, Radames Sierra-Zorita7 and Ricardo Xavier8, 1Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, 2University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 3Emeritus Research and Monash University, Melbourne, Australia, 4University of California San Diego, La Jolla, CA, 5Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, 6AbbVie, Inc., North Chicago, IL, 7University of Puerto Rico, San Juan, Puerto Rico, 8Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

    Background/Purpose: Early predictors of response to treatment with upadacitinib (UPA), an oral Janus kinase inhibitor, could help to optimize a treat-to-target approach in patients with…
  • Abstract Number: 0303 • ACR Convergence 2022

    Effectiveness of Upadacitinib in the Treatment of Rheumatoid Arthritis: Analysis of 6-Month Real-World Data from the United Rheumatology Normalized Integrated Community Evidence (UR-NICETM) Database

    Allan Gibofsky1, Mark Pearson2, Andrew Concoff3, Anna K Shmagel4, Patrick Zueger4, Yanna Song4, Lauren Smith5 and Grace Wright6, 1Weill Cornell Medical College and Hospital for Special Surgery, New York, NY, 2West Suburban Center for Arthritis, Milwaukee, WI, 3United Rheumatology, Hauppauge, NY, 4AbbVie, Inc., North Chicago, IL, 5AbbVie, Inc., Chicago, IL, 6Grace C Wright MD PC, Association of Women in Rheumatology, New York, NY

    Background/Purpose: The efficacy of upadacitinib (UPA), an oral Janus kinase inhibitor (JAKi), in the treatment of rheumatoid arthritis (RA) has been demonstrated in the phase…
  • Abstract Number: 0501 • ACR Convergence 2022

    Single-molecule Spatial Transcriptomic Analysis Reveals Distinct Cellular Networks in Rheumatoid Arthritis Synovia

    Roopa Madhu1, Kartik Bhamidipati1, Nghia Millard2, Michelle Curtis2, Ye Cui3, Youngmi Kim3, Ellen Gravallese4, Soumya Raychaudhuri1, Michael Brenner4, ilya Korsunsky1 and Kevin Wei5, 1Brigham and Women's Hospital, Boston, MA, 2Broad Institute, Boston, MA, 3Nanostring Technologies Inc., Seattle, WA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Chronic joint inflammation in rheumatoid arthritis (RA) arises from the interactions of many cell types. Single-cell transcriptomic profiling of RA joints has identified novel…
  • Abstract Number: 0578 • ACR Convergence 2022

    Interleukin-6 Trans-Signaling Induces Synovial Fibroblast Invasiveness by Utilizing Ets2 Protein

    Anil Singh, Paul Panipinto, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease with a complex interplay of synovial cells and soluble factors that create the signatures of chronic inflammation…
  • Abstract Number: 0601 • ACR Convergence 2022

    Occupational Inhaled Agents Constitute Major Risk Factors for Rheumatoid Arthritis, Particularly in the Context of Genetic Predisposition and Smoking

    Bowen Tang1, Qianwen Liu2, Anna Ilar3, Pernilla Wiebert2, Sara Hägg1, Leonid Padyukov2, Lars Klareskog2, Lars Alfredsson2 and Xia Jiang2, 1Karolinska Institutet, Solna, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3The National Board of Health and Welfare, Stockholm, Sweden

    Background/Purpose: The lung is recognized as a primary site in the induction of rheumatoid arthritis (RA). Our study aims to assess the effect of common…
  • Abstract Number: 0619 • ACR Convergence 2022

    Differences Between Patients in Remission with Active Rheumatoid Arthritis by Histological and Molecular Comparisons

    Selina Ohl1, Klaus Frommer2, Markus Rickert3, Stefan Rehart4, Ulf Müller-Ladner5 and Elena Neumann6, 1Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, 2Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, 3Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, Gießen, Germany, 4Agaplesion Markus Hospital, Dpt of Orthopaedics and Trauma Surgery, Frankfurt, Germany, 5JLU Campus KK, Bad Nauheim, Germany, 6JLU Gießen, Campus Kerckhoff, Bad Nauheim, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose inflammatory processes in the synovium lead to the destruction of cartilage and bone. Although there…
  • Abstract Number: 0722 • ACR Convergence 2022

    Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry

    Alejandro Brigante1, Rosana Quintana2, Carolina Isnardi3, Karen Roberts4, Gimena Gomez5, Maria Haye Salinas6, Enrique Soriano7, Guillermo Pons-Estel8, Maria De la Vega8, Osvaldo kerzberg7, Julieta Gamba7, Anastasia Secco9, Gustavo Citera10, Cesar Graf7, Veronica Savio11, Maria de los Angeles Gallardo7, Nora Aste7, Mercedes A Garcia12, Gustavo Casado7, Carla Gobbi7, Graciela Gomez7, Joan Manuel Dapeña13, Guillermo Berbotto7, Malena Viola7, Jonathan Rebak7, Diana Dubinsky7, Veronica Saurit14, Ingrid Petkovic7, Ana Bertoli7, Erika Catay7, C Leoni7, Ida Elena Exeni7, Bernardo Pons-Estel15, Sergio Paira7, GH Bovea Castelblanco7, Mercedes De la Sota7, Dora Pereira7, Gustavo Medina7, Amelia Granel7, Maria s Larroude7, Analia Patricia Alvarez7, Santiago Agüero16, Cecilia Pisoni17, Monica Sacnun7 and Edson Velozo18, 1UNISAR, Lobos, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 3SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 4UNISAR, Rosario, Argentina, 5Sanatorio Guemes, Buenos Aires, Argentina, 6UNLAR, La Rioja, Argentina, 7On behalf of the BIOBADASAR 3.0 registry, Buenos Aires, Argentina, 8Argentine Society of Rheumatology, Buenos Aires, Argentina, 9Rivadavia Hospital, Buenos Aires, Argentina, 10Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, 11Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, 12HIGA San Martin, La Plata, Argentina, 13Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina, 14Hospital Privado Universitario, Cordoba, Argentina, 15Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 16Centro de Rehabilitación Dr Mauricio Figueroa, Catamarca, Argentina, 17CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, 18SAR COVID Investigator, Caba

    Background/Purpose: Major adverse cardiovascular events (MACE) and neoplasms are a concern in autoimmune diseases. RA and PsA are diseases where inflammation plays a key role…
  • Abstract Number: 0786 • ACR Convergence 2022

    Humoral and T-cell Responses to SARS-CoV-2 Vaccination in Patients with Rheumatoid Arthritis

    Carolina A Isnardi1, Osvaldo Luis Cerda1, MARGARITA LANDI2, Leonel Cruces3, Emilce Edith Schneeberger1, Claudia Calle montoro2, Maria Agustina Alfaro4, Brian Manases roldan4, Andrea Belen Gomez Vara1, Pamela Giorgis4, Roberto Alejandro Ezquer4, María G Crespo Rocha4, Camila R Reyes Gómez4, maria de los angeles correa4, Marcos Rosemffet5, Virginia Carrizo Abarza4, Santiago Catalan Pellet6, Miguel Perandones4, Cecilia Reimundes7, Yesica Longueira3, Gabriela Turk3, María Florencia Quiroga3, Natalia Laufer3, Rosana Quintana8, Maria De la Vega9, Nicolás Kreplak10, Marina Pifano10, Pablo Maid2, Guillermo Pons-Estel11 and Gustavo Citera1, 1Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, 2Austral University Hospital, Rheumatology Department, Buenos Aires, Argentina, 3Universidad de Buenos Aires. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS). Facultad de Medicina, Buenos Aires, Argentina, 4Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 5Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 6Austral University Hospital, Rheumatology Department, Lincoln, Argentina, 7Austral University Hospital, Rheumatology Department, Pilar, Argentina, 8Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 9Argentine Society of Rheumatology, Buenos Aires, Argentina, 10Ministry of Health of the Province of Buenos Aires, Buenos Aires, Argentina, 11CREAR, Rosario, Argentina

    Background/Purpose: Patients with immune mediated diseases achieve lower seroconversion rates to COVID19 vaccines compared to healthy controls, which is why these patients are a prioritized…
  • « Previous Page
  • 1
  • …
  • 95
  • 96
  • 97
  • 98
  • 99
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology